-
1
-
-
33746430408
-
Drugging the cancer kinome: Progress and challenges in developing personalized molecular cancer therapeutics
-
WORKMAN, P. 2005. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. Cold Spring Harb. Symp. Quant. Biol. 70: 499-515.
-
(2005)
Cold Spring Harb. Symp. Quant. Biol
, vol.70
, pp. 499-515
-
-
WORKMAN, P.1
-
2
-
-
33751106653
-
New approaches to molecular cancer therapeutics
-
COLLINS, I & P. WORKMAN. 2006. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2: 689-700.
-
(2006)
Nat. Chem. Biol
, vol.2
, pp. 689-700
-
-
COLLINS, I.1
WORKMAN, P.2
-
3
-
-
33749447286
-
AKT and cancer-is it all mTOR?
-
ROSEN, N & Q.B. SHE. 2006. AKT and cancer-is it all mTOR? Cancer Cell. 10: 254-256.
-
(2006)
Cancer Cell
, vol.10
, pp. 254-256
-
-
ROSEN, N.1
SHE, Q.B.2
-
5
-
-
0037025173
-
Cancer. Addiction to oncogenes - the Achilles heal of cancer
-
WEINSTEIN, I.B. 2002. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297: 63-64.
-
(2002)
Science
, vol.297
, pp. 63-64
-
-
WEINSTEIN, I.B.1
-
6
-
-
33749993417
-
The consensus coding sequences of human breast and colorectal cancers
-
SJOBLOM, T., S. JONES, L.D. WOOD, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
-
(2006)
Science
, vol.314
, pp. 268-274
-
-
SJOBLOM, T.1
JONES, S.2
WOOD, L.D.3
-
7
-
-
33947101019
-
Patterns of somatic mutation in human cancer genomes
-
GREENMAN, C., P. STEPHENS, R. SMITH, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
-
(2007)
Nature
, vol.446
, pp. 153-158
-
-
GREENMAN, C.1
STEPHENS, P.2
SMITH, R.3
-
8
-
-
32944457518
-
mTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
O'REILLY, K.E., F. ROJO, Q.B. SHE, et al. 2006.mTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66: 1500-1508.
-
(2006)
Cancer Res
, vol.66
, pp. 1500-1508
-
-
O'REILLY, K.E.1
ROJO, F.2
SHE, Q.B.3
-
9
-
-
26644449670
-
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
-
SHE, Q.B., D.B. SOLIT, Q. YE, et al. 2005. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297.
-
(2005)
Cancer Cell
, vol.8
, pp. 287-297
-
-
SHE, Q.B.1
SOLIT, D.B.2
YE, Q.3
-
11
-
-
1542298267
-
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
-
WORKMAN, P. 2004. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 206: 149-157.
-
(2004)
Cancer Lett
, vol.206
, pp. 149-157
-
-
WORKMAN, P.1
-
12
-
-
33746191768
-
Inhibitors of the HSP90 molecular chaperone: Current status
-
SHARP, S. & P. WORKMAN. 2006. Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res. 95: 323-348.
-
(2006)
Adv. Cancer Res
, vol.95
, pp. 323-348
-
-
SHARP, S.1
WORKMAN, P.2
-
13
-
-
4344674482
-
Targeting multiple signal transduction pathways through inhibition of Hsp90
-
ZHANG, H. & F. BURROWS. 2004. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 82: 488-499.
-
(2004)
J. Mol. Med
, vol.82
, pp. 488-499
-
-
ZHANG, H.1
BURROWS, F.2
-
14
-
-
34250162144
-
Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells
-
XU, W. & L. NECKERS. 2007. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res. 13: 1625-1629.
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 1625-1629
-
-
XU, W.1
NECKERS, L.2
-
15
-
-
33746417580
-
Hsp90: A novel target for cancer therapy
-
SOLIT, D.B. & N. ROSEN. 2006. Hsp90: a novel target for cancer therapy. Curr. Top. Med. Chem. 6: 1205-1214.
-
(2006)
Curr. Top. Med. Chem
, vol.6
, pp. 1205-1214
-
-
SOLIT, D.B.1
ROSEN, N.2
-
17
-
-
25844519550
-
HSP90 and the chaperoning of cancer
-
WHITESELL, L.& S. LINDQUIST. 2005. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5: 761-772.
-
(2005)
Nat. Rev. Cancer
, vol.5
, pp. 761-772
-
-
WHITESELL, L.1
LINDQUIST, S.2
-
18
-
-
34250561475
-
A new puffing pattern induced by temperature shock and DNP in Drosophila
-
RITOSSA, F. 1962. A new puffing pattern induced by temperature shock and DNP in Drosophila. Experentia 19: 571-573.
-
(1962)
Experentia
, vol.19
, pp. 571-573
-
-
RITOSSA, F.1
-
19
-
-
0030154255
-
Discovery of the heat shock response
-
RITOSSA, F. 1996. Discovery of the heat shock response. Cell Stress Chaperones 1: 97-98.
-
(1996)
Cell Stress Chaperones
, vol.1
, pp. 97-98
-
-
RITOSSA, F.1
-
20
-
-
33746364784
-
Structure and mechanism of Hsp90 molecular chaperone machinery
-
PEARL, L.H. & C. PRODROMOU. 2006. Structure and mechanism of Hsp90 molecular chaperone machinery. Ann. Rev. Biochem. 75: 271-294.
-
(2006)
Ann. Rev. Biochem
, vol.75
, pp. 271-294
-
-
PEARL, L.H.1
PRODROMOU, C.2
-
21
-
-
15544372341
-
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex
-
XU, W., X. YUAN, Z. XIANG, et al. 2005. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 12: 120-126.
-
(2005)
Nat. Struct. Mol. Biol
, vol.12
, pp. 120-126
-
-
XU, W.1
YUAN, X.2
XIANG, Z.3
-
22
-
-
34248195608
-
High HSP90 expression is associated with decreased survival in breast cancer
-
PICK, E., Y. KLUGER, J.M. GILTNANE, et al. 2007. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 67: 2932-2937.
-
(2007)
Cancer Res
, vol.67
, pp. 2932-2937
-
-
PICK, E.1
KLUGER, Y.2
GILTNANE, J.M.3
-
23
-
-
33746379315
-
Using natural product inhibitors to validate HSP90 as a molecular target in cancer
-
NECKERS, L. 2006. Using natural product inhibitors to validate HSP90 as a molecular target in cancer. Curr. Med. Chem. 6: 1163-1171.
-
(2006)
Curr. Med. Chem
, vol.6
, pp. 1163-1171
-
-
NECKERS, L.1
-
24
-
-
0141819958
-
The stress response: Implications for the development of Hp90 inhibitors
-
WHITESELL, L., R. BAGATELL & R. FALSEY. 2003. The stress response: implications for the development of Hp90 inhibitors. Curr. Cancer Drug Targets 3: 349-358.
-
(2003)
Curr. Cancer Drug Targets
, vol.3
, pp. 349-358
-
-
WHITESELL, L.1
BAGATELL, R.2
FALSEY, R.3
-
26
-
-
0141484615
-
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
-
KAMAL, A., L. THAO, J. SENSINTAFFAR, et al. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
-
(2003)
Nature
, vol.425
, pp. 407-410
-
-
KAMAL, A.1
THAO, L.2
SENSINTAFFAR, J.3
-
27
-
-
28244444919
-
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
-
DA ROCHA DIAS, S., F. FRIEDLOS, Y. LIGHT, et al. 2005. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65: 10686-10691.
-
(2005)
Cancer Res
, vol.65
, pp. 10686-10691
-
-
DA ROCHA DIAS, S.1
FRIEDLOS, F.2
LIGHT, Y.3
-
28
-
-
30444441778
-
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in Response to Hsp90 inhibitors
-
GRBOVIC, O.M., A.D. BASSO, A. SAWAI, et al. 2006. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in Response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. USA. 103: 57-62.
-
(2006)
Proc. Natl. Acad. Sci. USA
, vol.103
, pp. 57-62
-
-
GRBOVIC, O.M.1
BASSO, A.D.2
SAWAI, A.3
-
29
-
-
22244485706
-
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins
-
SHIMAMURA, T., A.M. LOWELL, J.A. ENGELMAN & G.I. SHAPIRO. 2005. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 65: 6401-6408.
-
(2005)
Cancer Res
, vol.65
, pp. 6401-6408
-
-
SHIMAMURA, T.1
LOWELL, A.M.2
ENGELMAN, J.A.3
SHAPIRO, G.I.4
-
30
-
-
0032569851
-
Hsp90 as a capacitor for morphological evolution
-
RUTHERFORD, S.L. & S. LINDQUIST. 1998. Hsp90 as a capacitor for morphological evolution. Nature 396: 336-342.
-
(1998)
Nature
, vol.396
, pp. 336-342
-
-
RUTHERFORD, S.L.1
LINDQUIST, S.2
-
31
-
-
34047237073
-
-
YEYATI, P.L., R.M. BANCEWICZ, J.M. MAULE & V. VAN HEYNINGEN. 2007. Hsp90 selectively modulates phenotype in vertebrate development. PLoS Genetics 43: 431-447.
-
YEYATI, P.L., R.M. BANCEWICZ, J.M. MAULE & V. VAN HEYNINGEN. 2007. Hsp90 selectively modulates phenotype in vertebrate development. PLoS Genetics 43: 431-447.
-
-
-
-
32
-
-
33746377987
-
Inhibitors of the HSP90 molecular chaperone: Attacking the master regulator in cancer
-
MCDONALD, E., P. WORKMAN & K. JONES. 2007. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr. Top. Med. Chem. 6: 1091-1107.
-
(2007)
Curr. Top. Med. Chem
, vol.6
, pp. 1091-1107
-
-
MCDONALD, E.1
WORKMAN, P.2
JONES, K.3
-
33
-
-
0028064940
-
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
-
WHITESELL, L., E.G. MIMNAUGH, B. DE COSTA, et al. 1994. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91: 8324-8328.
-
(1994)
Proc. Natl. Acad. Sci. USA
, vol.91
, pp. 8324-8328
-
-
WHITESELL, L.1
MIMNAUGH, E.G.2
DE COSTA, B.3
-
34
-
-
0032554763
-
Targeting of the protein chaperone HSP90, by the transformation suppressing agent, radicicol
-
SHARMA, S.V., T. AGATSUMA & H. NAKANO. 1998. Targeting of the protein chaperone HSP90, by the transformation suppressing agent, radicicol. Oncogene 16: 2639-2645.
-
(1998)
Oncogene
, vol.16
, pp. 2639-2645
-
-
SHARMA, S.V.1
AGATSUMA, T.2
NAKANO, H.3
-
35
-
-
0141596941
-
Overview: Translating Hsp90 biology into Hsp90 drugs
-
WORKMAN, P. 2003. Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets 3: 297-300.
-
(2003)
Curr. Cancer Drug Targets
, vol.3
, pp. 297-300
-
-
WORKMAN, P.1
-
36
-
-
0032959590
-
Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
-
ROE, S.M., C. PRODROMOU, R. O'BRIEN, et al. 1999. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42: 260-266.
-
(1999)
J. Med. Chem
, vol.42
, pp. 260-266
-
-
ROE, S.M.1
PRODROMOU, C.2
O'BRIEN, R.3
-
37
-
-
0036718795
-
ATPases as drug targets: Learning from their structure
-
CHENE, P. 2002. ATPases as drug targets: learning from their structure. Nat. Rev. Drug Discov. 1: 665-673.
-
(2002)
Nat. Rev. Drug Discov
, vol.1
, pp. 665-673
-
-
CHENE, P.1
-
39
-
-
23044441106
-
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
-
BANERJI, U., A O'DONNELL, M. SCURR, et al. 2005. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23: 4152-4161.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 4152-4161
-
-
BANERJI, U.1
O'DONNELL, A.2
SCURR, M.3
-
40
-
-
34250197902
-
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
-
SOLIT, D.B., S.P. IVY, C. KOPIL, et al. 2007. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res. 13: 1775-1782.
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 1775-1782
-
-
SOLIT, D.B.1
IVY, S.P.2
KOPIL, C.3
-
42
-
-
1942485334
-
17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models
-
BURGER A.M., H.H. FIEBIG, S.F. STINSON & E.A. SAUSVILLE. 2004. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15: 377-387.
-
(2004)
Anticancer Drugs
, vol.15
, pp. 377-387
-
-
BURGER, A.M.1
FIEBIG, H.H.2
STINSON, S.F.3
SAUSVILLE, E.A.4
-
43
-
-
33751258297
-
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anticancer agent directed against Hsp90
-
SYDOR J.R., E. NORMANT, C.S. PIEN, et al. 2006. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anticancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA 103: 17408-17413.
-
(2006)
Proc. Natl. Acad. Sci. USA
, vol.103
, pp. 17408-17413
-
-
SYDOR, J.R.1
NORMANT, E.2
PIEN, C.S.3
-
44
-
-
0033579175
-
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
-
KELLAND, L.R., S.Y. SHARP, P.M. ROGERS, et al. 1999. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 91: 1940-1949.
-
(1999)
J. Natl. Cancer Inst
, vol.91
, pp. 1940-1949
-
-
KELLAND, L.R.1
SHARP, S.Y.2
ROGERS, P.M.3
-
45
-
-
0034655207
-
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
-
ZHENG, F.F., S. KUDUK, G. CHIOSIS, et al. 2000. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 15: 20904-2094.
-
(2000)
Cancer Res
, vol.15
, pp. 20904-22094
-
-
ZHENG, F.F.1
KUDUK, S.2
CHIOSIS, G.3
-
46
-
-
33846629429
-
Dimeric ansamycins - a new class of antitumor Hsp90 modulators with prolonged inhibitory activity
-
ZHANG, H., Y.C. YANG, L. ZHANG, et al. 2006. Dimeric ansamycins - a new class of antitumor Hsp90 modulators with prolonged inhibitory activity. Int. J. Cancer 120: 918-926.
-
(2006)
Int. J. Cancer
, vol.120
, pp. 918-926
-
-
ZHANG, H.1
YANG, Y.C.2
ZHANG, L.3
-
48
-
-
28144440479
-
Heat shock protein 90 inhibitors. A text book example of medicinal chemistry?
-
JANIN, Y.L. 2005. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J. Med. Chem. 48: 7503-7512.
-
(2005)
J. Med. Chem
, vol.48
, pp. 7503-7512
-
-
JANIN, Y.L.1
-
49
-
-
0035071607
-
A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
-
CHIOSIS, G., M.N. TIMAUL, B. LUCAS, et al. 2001. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8: 289-299.
-
(2001)
Chem. Biol
, vol.8
, pp. 289-299
-
-
CHIOSIS, G.1
TIMAUL, M.N.2
LUCAS, B.3
-
50
-
-
33746365169
-
Discovery and development of purine-scaffold Hsp90 inhibitors
-
CHIOSIS, G. 2006. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 6: 1183-1191.
-
(2006)
Curr. Top. Med. Chem
, vol.6
, pp. 1183-1191
-
-
CHIOSIS, G.1
-
51
-
-
3042637928
-
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms
-
WRIGHT, L., X. BARRIL, B. DYMOCK, et al. 2004. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 11: 775-785.
-
(2004)
Chem. Biol
, vol.11
, pp. 775-785
-
-
WRIGHT, L.1
BARRIL, X.2
DYMOCK, B.3
-
52
-
-
17444416142
-
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90
-
LLAUGER, L., H. HE, J. KIM, et al. 2005. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 48: 2892-2905.
-
(2005)
J. Med. Chem
, vol.48
, pp. 2892-2905
-
-
LLAUGER, L.1
HE, H.2
KIM, J.3
-
53
-
-
33747500679
-
7′-Substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors
-
ZHANG, L., J. FAN, K. VU, et al. 2006. 7′-Substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors. J. Med. Chem. 49: 5352-5362.
-
(2006)
J. Med. Chem
, vol.49
, pp. 5352-5362
-
-
ZHANG, L.1
FAN, J.2
VU, K.3
-
54
-
-
20644448390
-
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors
-
CHEUNG, K.M., T.P. MATTHEWS, K. JAMES, et al. 2005. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 15: 3338-3343.
-
(2005)
Bioorg. Med. Chem. Lett
, vol.15
, pp. 3338-3343
-
-
CHEUNG, K.M.1
MATTHEWS, T.P.2
JAMES, K.3
-
55
-
-
33947210121
-
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors
-
SHARP, S.Y., K. BOXALL, M. ROWLANDS, et al. 2007. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res. 67: 2206-2216.
-
(2007)
Cancer Res
, vol.67
, pp. 2206-2216
-
-
SHARP, S.Y.1
BOXALL, K.2
ROWLANDS, M.3
-
56
-
-
21244505104
-
Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design
-
DYMOCK, B.W., X. BARRILL, P.A. BROUGH, et al. 2005. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 48: 4212-4215.
-
(2005)
J. Med. Chem
, vol.48
, pp. 4212-4215
-
-
DYMOCK, B.W.1
BARRILL, X.2
BROUGH, P.A.3
-
57
-
-
34248166042
-
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
-
SHARP, S.Y, C. PRODROMOU, K. BOXALL, et al. 2007. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 6: 1198-1211.
-
(2007)
Mol. Cancer Ther
, vol.6
, pp. 1198-1211
-
-
SHARP, S.Y.1
PRODROMOU, C.2
BOXALL, K.3
-
58
-
-
0034711270
-
The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone
-
MARCU, M.G., A. CHADLI, I. BOUHOUCHE, et al. 2000. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275: 37181-37186.
-
(2000)
J. Biol. Chem
, vol.275
, pp. 37181-37186
-
-
MARCU, M.G.1
CHADLI, A.2
BOUHOUCHE, I.3
-
59
-
-
0034594644
-
Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins
-
MARCU, M.G., T.W. SCHULTE & L. NECKERS. 2000. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 92: 242-248.
-
(2000)
J. Natl. Cancer Inst
, vol.92
, pp. 242-248
-
-
MARCU, M.G.1
SCHULTE, T.W.2
NECKERS, L.3
-
60
-
-
25144435448
-
Hsp90 inhibitors identified from a library of novobiocin analogues
-
YU, X.M., G. SHEN, L. NECKERS, et al. 2005. Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 127:12778-12779.
-
(2005)
J. Am. Chem. Soc
, vol.127
, pp. 12778-12779
-
-
YU, X.M.1
SHEN, G.2
NECKERS, L.3
-
61
-
-
33845306864
-
Novobiocin: Redesigning a DNA gyrase inhibitor for selective inhibition of hsp90
-
BURLISON, J.A., L. NECKERS, A.B. SMITH, et al. 2006. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J. Am. Chem. Soc. 128: 15529-15536.
-
(2006)
J. Am. Chem. Soc
, vol.128
, pp. 15529-15536
-
-
BURLISON, J.A.1
NECKERS, L.2
SMITH, A.B.3
-
62
-
-
0037012344
-
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228
-
YU, X., M.G. GUO, L. NECKERS, D.M. NQUYEN, et al. 2002. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94: 504-513.
-
(2002)
J. Natl. Cancer Inst
, vol.94
, pp. 504-513
-
-
YU, X.1
GUO, M.G.2
NECKERS, L.3
NQUYEN, D.M.4
-
63
-
-
22844432021
-
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors
-
BALI P, M. PRANPAT, J. BRADNER, et al. 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280: 26729-26734.
-
(2005)
J. Biol. Chem
, vol.280
, pp. 26729-26734
-
-
BALI, P.1
PRANPAT, M.2
BRADNER, J.3
-
64
-
-
33846014703
-
An acetylation site in the middle domain of Hsp90 regulates chaperone function
-
SCROGGINS, B.T., K. ROBZYK, D. WANG, et al. 2007. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell. 25: 151-159.
-
(2007)
Mol. Cell
, vol.25
, pp. 151-159
-
-
SCROGGINS, B.T.1
ROBZYK, K.2
WANG, D.3
-
65
-
-
0034710542
-
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone
-
CLARKE, P.A., I. HOSTEIN, U. BANERJI, et al. 2000. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19: 4125-4133.
-
(2000)
Oncogene
, vol.19
, pp. 4125-4133
-
-
CLARKE, P.A.1
HOSTEIN, I.2
BANERJI, U.3
-
66
-
-
33749433916
-
Gene expression signaturebased chemical genomic prediction identifies a novel class of HSP90 pathway modulators
-
HIERONYMUS, H., J. LAMB, K.N. ROSS, et al. 2006. Gene expression signaturebased chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10: 321-330.
-
(2006)
Cancer Cell
, vol.10
, pp. 321-330
-
-
HIERONYMUS, H.1
LAMB, J.2
ROSS, K.N.3
-
67
-
-
0037636527
-
Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90
-
MATTHEWS, R.C., C. RIGG, S. HODGETTS, et al. 2003. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47: 2208-2216.
-
(2003)
Antimicrob. Agents Chemother
, vol.47
, pp. 2208-2216
-
-
MATTHEWS, R.C.1
RIGG, C.2
HODGETTS, S.3
-
68
-
-
26444482073
-
Pharmacokineticpharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models
-
BANERJI, U., M. WALTON, F. RAYNAUD, et al. 2005. Pharmacokineticpharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin. Cancer Res. 11: 7023-7032.
-
(2005)
Clin. Cancer Res
, vol.11
, pp. 7023-7032
-
-
BANERJI, U.1
WALTON, M.2
RAYNAUD, F.3
-
69
-
-
33745086222
-
Identification of new biomarkers for clinical trials of Hsp90 inhibitors
-
ZHANG, H., D. CHUNG, Y.C. YANG, et al. 2006. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol. Cancer Ther. 5: 1256-1264.
-
(2006)
Mol. Cancer Ther
, vol.5
, pp. 1256-1264
-
-
ZHANG, H.1
CHUNG, D.2
YANG, Y.C.3
-
70
-
-
34147150867
-
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin
-
MALONEY, A., P.A. CLARKE, S. NAABY- HANSEN, et al. 2007. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 67: 3239-5323.
-
(2007)
Cancer Res
, vol.67
, pp. 3239-5323
-
-
MALONEY, A.1
CLARKE, P.A.2
NAABY- HANSEN, S.3
-
71
-
-
33745574028
-
Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET
-
SMITH-JONES, P.M., D. SOLIT, F. AFROZE, et al. 2006. Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET. J. Nucl. Med. 47: 793-796.
-
(2006)
J. Nucl. Med
, vol.47
, pp. 793-796
-
-
SMITH-JONES, P.M.1
SOLIT, D.2
AFROZE, F.3
-
72
-
-
0344393470
-
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models
-
CHUNG, Y.L., H. TROY, U. BANERJI, et al. 2003. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl. Cancer Inst. 95: 1624-1633.
-
(2003)
J. Natl. Cancer Inst
, vol.95
, pp. 1624-1633
-
-
CHUNG, Y.L.1
TROY, H.2
BANERJI, U.3
-
73
-
-
20044382800
-
Navigating the chaperone network: An interactive map of physical and genetic interactions mediated by the Hsp90 chaperone
-
ZHAO, R. , M. DAVEY, H. YA-CHIEH, et al. 2005. Navigating the chaperone network: an interactive map of physical and genetic interactions mediated by the Hsp90 chaperone. Cell 120: 715-727.
-
(2005)
Cell
, vol.120
, pp. 715-727
-
-
ZHAO, R.1
DAVEY, M.2
YA-CHIEH, H.3
-
74
-
-
33845804718
-
Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity
-
XU, W., X. YUAN, K. BEEBE, et al. 2007. Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity. Mol. Cell Biol. 27: 220-228.
-
(2007)
Mol. Cell Biol
, vol.27
, pp. 220-228
-
-
XU, W.1
YUAN, X.2
BEEBE, K.3
-
75
-
-
33746628448
-
Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
-
KOGA, F., W. XU, T.S. KARPOVA, et al. 2006. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc. Natl. Acad. Sci. USA 103: 11318-1122.
-
(2006)
Proc. Natl. Acad. Sci. USA
, vol.103
, pp. 11318-21122
-
-
KOGA, F.1
XU, W.2
KARPOVA, T.S.3
-
76
-
-
0037444766
-
Heat shock protein 90 and Cdc37 interact with LKB1 and regulate its stability
-
BOUDEAU, J., M. DEAK, M.A. LAWLOR, et al. 2003. Heat shock protein 90 and Cdc37 interact with LKB1 and regulate its stability. Biochem. J. 370: 849-857.
-
(2003)
Biochem. J
, vol.370
, pp. 849-857
-
-
BOUDEAU, J.1
DEAK, M.2
LAWLOR, M.A.3
-
77
-
-
0346057795
-
Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37
-
NONY, P., H. GAUDE, M. ROSSEL, et al. 2003. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37. Oncogene 22: 9165-9175.
-
(2003)
Oncogene
, vol.22
, pp. 9165-9175
-
-
NONY, P.1
GAUDE, H.2
ROSSEL, M.3
-
78
-
-
2442464375
-
Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG
-
FICKER, E, A.T. DENNIS, L. WANG, et al. 2003. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG. Circ. Res. 92:87-100.
-
(2003)
Circ. Res
, vol.92
, pp. 87-100
-
-
FICKER, E.1
DENNIS, A.T.2
WANG, L.3
-
79
-
-
33847708258
-
Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury
-
GABRIELSON, K., D. BEDJA, S. PIN, et al. 2007. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res. 67: 1436-1441.
-
(2007)
Cancer Res
, vol.67
, pp. 1436-1441
-
-
GABRIELSON, K.1
BEDJA, D.2
PIN, S.3
-
80
-
-
21144432950
-
Heat shock protein 90 inhibitor, 17-allylamino-17- demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line
-
PRICE, J.T., J.M.W. QUINN, N.A. SIMS, et al. 2005. Heat shock protein 90 inhibitor, 17-allylamino-17- demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res. 65: 4929-4938.
-
(2005)
Cancer Res
, vol.65
, pp. 4929-4938
-
-
PRICE, J.T.1
QUINN, J.M.W.2
SIMS, N.A.3
-
81
-
-
33645470397
-
Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis
-
SANDERSON, S, M. VALENTI, S. GOWAN, et al. 2006. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol. Cancer Ther. 5: 522-532.
-
(2006)
Mol. Cancer Ther
, vol.5
, pp. 522-532
-
-
SANDERSON, S.1
VALENTI, M.2
GOWAN, S.3
-
82
-
-
0037119415
-
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway
-
ISAACS, J.S., Y.J. JUNG, E.G. MIMNAUGH, et al. 2002. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277: 29936-29944.
-
(2002)
J. Biol. Chem
, vol.277
, pp. 29936-29944
-
-
ISAACS, J.S.1
JUNG, Y.J.2
MIMNAUGH, E.G.3
-
83
-
-
33749352630
-
Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade
-
MIMNAUGH, E.G., W. XU, M. VOS, et al. 2006. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol. Cancer Res. 4: 667-681.
-
(2006)
Mol. Cancer Res
, vol.4
, pp. 667-681
-
-
MIMNAUGH, E.G.1
XU, W.2
VOS, M.3
-
84
-
-
0034890377
-
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner
-
BASSO, A., D. SOLIT, L. NORTON, et al. 2001. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res. 7: 2228-2236.
-
(2001)
Clin. Cancer Res
, vol.7
, pp. 2228-2236
-
-
BASSO, A.1
SOLIT, D.2
NORTON, L.3
-
85
-
-
33745071182
-
Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT
-
SAIN, N, B. KRISHNAN, M.G. ORMEROD, et al. 2006. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol. Cancer Ther. 5: 1197-1208.
-
(2006)
Mol. Cancer Ther
, vol.5
, pp. 1197-1208
-
-
SAIN, N.1
KRISHNAN, B.2
ORMEROD, M.G.3
-
86
-
-
33847369469
-
A high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins
-
DICKEY, C.A., A. KAMAL, K. LUNDGREN, et al. 2007. A high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117: 648-658.
-
(2007)
J. Clin. Invest
, vol.117
, pp. 648-658
-
-
DICKEY, C.A.1
KAMAL, A.2
LUNDGREN, K.3
-
87
-
-
33750842131
-
Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis
-
WANG, X., J. VENABLE, P. LAPOINTE, et al. 2006. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127: 803-815.
-
(2006)
Cell
, vol.127
, pp. 803-815
-
-
WANG, X.1
VENABLE, J.2
LAPOINTE, P.3
-
88
-
-
34147099104
-
A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation
-
HARDCASTLE, A., P. TOMLIN, C. NORRIS, et al. 2007. A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation. Mol. Cancer Ther. 6: 1112-1122.
-
(2007)
Mol. Cancer Ther
, vol.6
, pp. 1112-1122
-
-
HARDCASTLE, A.1
TOMLIN, P.2
NORRIS, C.3
|